Baird Maintains Outperform on Climb Bio, Raises Price Target to $12
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Baird analyst Colleen Kusy maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $9 to $12.
Baird analyst Colleen Kusy maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $9 to $12.